Fact Source: Financial Supervisory Service DART
💡 3-Second Summary
Celltrion announced that the U.S. Food and Drug Administration (FDA) has approved its global Phase 3 clinical trial plan for CT-P55 to evaluate efficacy and safety compared with Cosentyx in patients with plaque psoriasis.
📊 [Key Disclosure Details & Financial Highlights]
- Overview
- Title: Approval of Phase 3 Clinical Trial Plan for CT-P55 (Cosentyx Biosimilar) in the U.S.
- Application Date: June 28, 2024 (Local Time)
- Approval Date: August 13, 2024 (Local Time)
- Regulatory Authority: U.S. Food and Drug Administration (FDA)
- Board Resolution or Fact Confirmation Date: August 13, 2024 (Date of confirming trial plan approval from the U.S. FDA)
- Clinical Trial Details
- Trial Phase: Global Phase 3 Clinical Trial
- Indication: Plaque Psoriasis
- Clinical Trial Registration Number: EU CT number 2024-513348-27-00
- Objective: To compare efficacy and safety between CT-P55 and Cosentyx to demonstrate biosimilarity
- Number of Subjects: 375 patients
- Trial Duration: 56 weeks
- Study Design: Randomized, active-controlled, double-blind, Phase 3 clinical trial
- Future Plans & Important Notes
- Celltrion aims to demonstrate biosimilarity to the reference drug Cosentyx through efficacy and safety outcomes in this Phase 3 trial.
- Statistically, the probability of a clinical-stage drug candidate receiving final market authorization is known to be around 10%, and commercialization plans may be modified or abandoned depending on trial outcomes.
📝 Editor’s Comment (Key Follow-up Checkpoint)
📌 Monitoring U.S. Phase 3 Trial Initiation and Subsequent Disclosures
This disclosure reports the formal approval from the U.S. FDA for the Phase 3 clinical trial plan of CT-P55 (Cosentyx biosimilar). Tracking whether patient recruitment and dosing proceed as scheduled following this approval is important for assessing the actual execution of the trial toward pipeline development. Detailed updates can be verified in subsequent regulatory disclosures and upcoming periodic reports (Quarterly, Half-Yearly, or Annual Reports).
📢 Disclaimer & Source Notice
Source: This content has been newly structured and created based on official submission data from the Financial Supervisory Service’s Data Analysis, Retrieval and Transfer System (DART).
Investment Risk Warning: This content is provided for informational and linguistic reference purposes only. Under no circumstances does it constitute financial advice or a recommendation to buy or sell specific stocks. All investment decisions and financial responsibilities rest solely with the investor.
Contact: For compliance inquiries or copyright requests, please contact ksb220805@gmail.com.
